Pharma: Clinic Roundup
Wednesday, February 22, 2012
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy, including tumor necrosis factor-alpha antagonists. Both phases of the year-long trial met their primary endpoints, providing statistically significant improvements in clinical response in the six-week induction phase and clinical remission in the subsequent maintenance phase.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.